135 related articles for article (PubMed ID: 19223878)
41. For payers, cost is the downside of continuing cardiovascular outcomes trials in current form.
Snow K
Am J Manag Care; 2018 Dec; 24(14 Spec No.):SP606. PubMed ID: 30620543
[No Abstract] [Full Text] [Related]
42. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
[TBL] [Abstract][Full Text] [Related]
43. Diabetes and the menopause.
Wedisinghe L; Perera M
Maturitas; 2009 Jul; 63(3):200-3. PubMed ID: 19535207
[TBL] [Abstract][Full Text] [Related]
44. US proposes more stringent conflict-of-interest rules.
Kondro W
CMAJ; 2007 May; 176(11):1571-2. PubMed ID: 17515579
[No Abstract] [Full Text] [Related]
45. Editorial comment.
Walson PD; Mullins CD; Lyles A; West JA
Clin Ther; 2008 Oct; 30(10):1889. PubMed ID: 19014844
[No Abstract] [Full Text] [Related]
46. Current trends in treating type 2 diabetes.
Hollander PA
Postgrad Med; 2000 May; 107(6 Suppl Key):4-10. PubMed ID: 19667504
[TBL] [Abstract][Full Text] [Related]
47. Do diabetes drugs modify the risk of pancreatic cancer?
Yang YX
Gastroenterology; 2009 Aug; 137(2):412-5. PubMed ID: 19563838
[No Abstract] [Full Text] [Related]
48. Balancing risk and benefit with oral hypoglycemic drugs.
Hamnvik OP; McMahon GT
Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
[TBL] [Abstract][Full Text] [Related]
49. [Monitoring of cardiovascular risk factors in patients with diabetes type 2].
Petrlová B; Rosolová H; Simon J; Sefrna F; Sifalda P; Sípová I
Vnitr Lek; 2009 Sep; 55(9):812-8. PubMed ID: 19785382
[TBL] [Abstract][Full Text] [Related]
50. FGF21: a novel prospect for the treatment of metabolic diseases.
Kharitonenkov A; Shanafelt AB
Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957
[TBL] [Abstract][Full Text] [Related]
51. Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.
Mathewkutty S; McGuire DK
Expert Rev Cardiovasc Ther; 2009 May; 7(5):541-9. PubMed ID: 19419262
[TBL] [Abstract][Full Text] [Related]
52. Research digest: CV trials in diabetes-looking ahead.
Preiss D; Sattar N
Lancet Diabetes Endocrinol; 2018 Oct; 6(10):769. PubMed ID: 30266187
[No Abstract] [Full Text] [Related]
53. Advisory committee; Risk Communication Advisory Committee; establishment. Final Rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Jul; 72(144):41221-2. PubMed ID: 17674496
[TBL] [Abstract][Full Text] [Related]
54. Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?
Khunti K; Davies MJ; Marx N; Buse JB
Lancet Diabetes Endocrinol; 2020 Oct; 8(10):810-811. PubMed ID: 32946819
[No Abstract] [Full Text] [Related]
55. Diabetes drugs pass cardiovascular risk check.
Opar A
Nat Rev Drug Discov; 2009 May; 8(5):343-4. PubMed ID: 19404302
[No Abstract] [Full Text] [Related]
56. [Type 2 diabetes, is it just a case of hyperglycemia? Confusion between the interests of science, humanity and the economy].
Ruiz J
Rev Med Suisse; 2009 Jun; 5(206):1280-2. PubMed ID: 19579424
[TBL] [Abstract][Full Text] [Related]
57. The diabetic, hypertensive heart: epidemiology and mechanisms of a very high-risk situation.
Franjic B; Marwick TH
J Hum Hypertens; 2009 Nov; 23(11):709-17. PubMed ID: 19516273
[TBL] [Abstract][Full Text] [Related]
58. Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?
Bosi E
Diabetes Obes Metab; 2009 May; 11 Suppl 2():3-8. PubMed ID: 19385978
[TBL] [Abstract][Full Text] [Related]
59. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs.
Hirshberg B; Raz I
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S101-6. PubMed ID: 21525438
[No Abstract] [Full Text] [Related]
60. [Oral antidiabetic agents for the general practitioner].
Siegmund T
MMW Fortschr Med; 2009 Apr; 151(14):86, 88-91; quiz 92. PubMed ID: 19504847
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
